Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Second phase 3 randomized study to the evaluate efficacy of Squalamine eye drops [OHR-102] and Lucentis injections compared with Lucentis monotherapy in patients with wet age-related macular degeneration

Next Previous
Trial Profile

Second phase 3 randomized study to the evaluate efficacy of Squalamine eye drops [OHR-102] and Lucentis injections compared with Lucentis monotherapy in patients with wet age-related macular degeneration

Status: Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 16 Feb 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Squalamine (Primary) ; Ranibizumab
  • Indications Wet age-related macular degeneration
  • Focus Registrational; Therapeutic Use
  • Sponsors Ohr Pharmaceutical

    • Most Recent Events

    • 14 Feb 2018 Status changed from planning to withdrawn prior to enrolment as company has discontinued further development of squalamine to preserve cash and to evaluatie strategic alternatives to maximize shareholder value, according to an Ohr Pharmaceutical media release.
    • 18 Apr 2016 Acording to Ohr Pharmaceuticals media release, this study will provide the data for regulatory approval in major ophthalmic markets worldwide.
    • 29 Mar 2016 According to Ohr Pharmaceutical media release, this trial is being conducted under a Special Protocol Assessment (SPA) with the US FDA.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top